# Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors

> **NCT02610361** · PHASE1 · COMPLETED · sponsor: **BeiGene** · enrollment: 131 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** BGB-283

## Key facts

- **NCT ID:** NCT02610361
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-20
- **Primary completion:** 2017-10
- **Final completion:** 2017-10
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02610361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02610361, "Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02610361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*